Progressive fibrosing interstitial lung disease: clinical uncertainties, consensus recommendations, and research priorities

…, L Richeldi, S Tomassetti, C Valenzuela… - The lancet Respiratory …, 2020 - thelancet.com
Within the spectrum of fibrosing interstitial lung diseases (ILDs) is a subset of patients who
have inexorable progression of pulmonary fibrosis despite treatment, which is known as the …

[HTML][HTML] Variability in global prevalence of interstitial lung disease

B Kaul, V Cottin, HR Collard, C Valenzuela - Frontiers in Medicine, 2021 - frontiersin.org
There are limited epidemiologic studies describing the global burden and geographic
heterogeneity of interstitial lung disease (ILD) subtypes. We found that among seventeen …

[HTML][HTML] Births: final data for 2020

…, BE Hamilton, JA Martin, AK Driscoll, CP Valenzuela - 2022 - stacks.cdc.gov
Objectives—This report presents 2020 data on US births according to a wide variety of
characteristics. Trends in fertility patterns and maternal and infant characteristics are described …

[HTML][HTML] Trial of a preferential phosphodiesterase 4B inhibitor for idiopathic pulmonary fibrosis

…, S Stowasser, C Valenzuela… - … England Journal of …, 2022 - Mass Medical Soc
Background Phosphodiesterase 4 (PDE4) inhibition is associated with antiinflammatory and
antifibrotic effects that may be beneficial in patients with idiopathic pulmonary fibrosis. …

Early diagnosis of fibrotic interstitial lung disease: challenges and opportunities

…, M Salisbury, N Sverzellati, C Valenzuela… - The Lancet …, 2021 - thelancet.com
Many patients with interstitial lung disease (ILD) develop pulmonary fibrosis, which can lead
to reduced quality of life and early mortality. Patients with fibrotic ILD often have …

Safety of nintedanib added to pirfenidone treatment for idiopathic pulmonary fibrosis

…, H Nunes, R Sussman, C Valenzuela… - European …, 2018 - Eur Respiratory Soc
We assessed safety and tolerability of treatment with pirfenidone (1602–2403 mg·day −1 )
and nintedanib (200–300 mg·day −1 ) in patients with idiopathic pulmonary fibrosis (IPF). This …

Biomarkers of extracellular matrix turnover in patients with idiopathic pulmonary fibrosis given nintedanib (INMARK study): a randomised, placebo-controlled study

…, B Safont, J Sellares, C Valenzuela… - The Lancet respiratory …, 2019 - thelancet.com
Background A hallmark of idiopathic pulmonary fibrosis is the excess accumulation of
extracellular matrix in the lungs. Degradation of extracellular matrix generates free-circulating …

Births: final data for 2021

…, BE Hamilton, JA Martin, AK Driscoll, CP Valenzuela - 2023 - stacks.cdc.gov
… D., and Claudia P. Valenzuela, MPH, Division of Vital Statistics … Osterman MJK,
Hamilton BE, Martin JA, Driscoll AK, Valenzuela CP. Births: Final data for 2020. National …

Ziritaxestat, a novel autotaxin inhibitor, and lung function in idiopathic pulmonary fibrosis: the ISABELA 1 and 2 randomized clinical trials

…, AN Barbero, JS Torres, C Valenzuela… - Jama, 2023 - jamanetwork.com
Importance There is a major need for effective, well-tolerated treatments for idiopathic
pulmonary fibrosis (IPF). Objective To assess the efficacy and safety of the autotaxin inhibitor …

Syndrome of combined pulmonary fibrosis and emphysema: an official ATS/ERS/JRS/ALAT research statement

…, N Sverzellati, T Tonia, C Valenzuela… - American journal of …, 2022 - atsjournals.org
Background: The presence of emphysema is relatively common in patients with fibrotic interstitial
lung disease. This has been designated combined pulmonary fibrosis and emphysema …